https://www.selleckchem.com/pr....oducts/hsp27-inhibit
Breast cancer odds ratio (OR) 9.25; 95 CI 1.91.-44.71; non-vesicant drug OR 1.37; 95 CI 0.13-14.95; vein diameter OR 0.40; 95% CI 0.16-0.97; fosaprepitant use OR 0.16; 95% CI, 0.18-10.32. CONCLUSIONS The induration incidence was 17.4%. Risk factors for induration following chemotherapy administration were breast cancer and smaller vein diameter. Abnormal cases of subcutaneous tissue were confirmed, including subcutaneous edema, thrombosis, and thickening of the vessel wall. Induration may be prevented by selecting larger diam
Like
Comment
Share
